Fig 1: Analyses of the functional role of P2RY14 gene in the tumor microenvironment (TME) and the underlying regulatory genes in HNSC. (A,B) The enriched gene sets in HALLMARK by the samples with high or low P2RY14 expression. (C) KEGG pathway analysis of the genes co-expressed with P2RY14. (D) The genes co-expressed with P2RY14 in the T-cell receptor signaling pathway and PD-L1 expression and PD-1 checkpoint pathway in cancer.
Fig 2: Expression of P2RY14 in samples of HNSC patients from the TCGA database and its correlation with survival and TNM staging distribution. (A) Differentiated expression of P2RY14 in normal and tumor samples. (B) Paired differentiation analysis of P2RY14 in the normal and tumor sample derived from the same patient. (C) Survival analysis for HNSC patients with different P2RY14 expression. (D–G) Distribution of P2RY14 expression level in clinical stage, T classification, N classification, and M classification.
Fig 3: The differentiated expression of P2RY14 in samples and correlation with survival and distribution of OSCC patients. (A) Representative immunohistochemical staining images of P2RY14 in tumor stroma from HNSC patients (scale bar: 50 µm). (B) Survival analysis for HNSC patients with different P2RY14 expression. (C–E) Distribution of P2RY14 expression level in clinical stage, T classification, and N classification.
Fig 4: Correlation of tumor-infiltrating immune cells proportion with P2RY14 expression. (A) Violin plots showing the ratio differentiation of 22 kinds of immune cells between HNSC tumor samples with high or low P2RY14 expression. (B) Scatter plot showing the correlation of eight kinds of tumor-infiltrating immune cells proportion with the P2RY14 expression.
Supplier Page from Abcam for Anti-P2Y14 antibody